Identifying High-Risk Groups Eligible for LTBI Testing
Certain factors identify persons at high risk for tuberculosis (TB) infection and/or progression to TB disease. According to the Centers for Disease Control and Prevention, persons in the high-risk groups listed in Persons with risk factors from both columns may be at much higher risk than those with risk factors in only one column. For example, an individual born in a high TB prevalence country with HIV infection is epidemiologically at much higher risk of having active TB than a U.S.-born individual with HIV infection.
In 2016, the United States Preventive Services Task Force (USPSTF) recommended screening for LTBI in populations at increased risk. Some clinicians may adopt these recommendations and initiate or expand LTBI screening for these persons. The USPSTF recommendation applies to asymptomatic adults who were born in, or are former residents of, countries with increased tuberculosis prevalence and persons who live in, or have lived in, high-risk congregate settings (e.g., homeless shelters and correctional facilities). The USPSTF did not review the evidence on screening in other populations that may be at high risk. 2  TABLE 1: PERSONS AT HIGH RISK FOR TUBERCULOSIS INFECTION AND PROGRESSION   TO TUBERCULOSIS DISEASE 3 
For Tuberculosis Infection For Progression to Tuberculosis Disease 4
 High-priority contacts such as housemates or coworkers or contacts of persons who have smearpositive pulmonary or laryngeal tuberculosis (TB)  Infants, children, and adolescents exposed to adults in high-risk categories  Recent immigrants (<5 years) from countries with high incidence of TB (Asian, African, Latin American, and Eastern European countries have TB rates 5-30 times higher than U.S. rates, and an increasing percentage of TB cases here are occurring among immigrants from those countries)  Migrant workers Latent TB infection is usually diagnosed when tests indicate TB infection (see below) and the patient has no evidence of active TB disease.
Diagnosis of Latent TB Infection

Diagnostic Testing Options
There are currently two methods available for the detection of M. tuberculosis infection in the United States. The two methods are:
1) Mantoux tuberculin skin test (TST; also known as a purified protein derivative (PPD) skin test) 2) Interferon-gamma release assays (IGRAs) 5 The diagnosis of latent tuberculosis infection (LTBI) has traditionally been based upon results of tuberculin skin testing. However, interferon-gamma release assays (IGRAs) are now the preferred method in certain situations, such as when an individual has a history of BCG vaccination or is unlikely to return to have their TST read. 6 Mantoux Tuberculin Skin Testing (TST; also known as a purified protein derivative (PPD) skin test)
The Mantoux method of tuberculin skin testing can be used to detect infection with Mycobacterium tuberculosis.
In general, it takes two to 10 weeks after TB infection for a person to develop a delayedtype immune response to the antigen tuberculin measurable with the Mantoux tuberculin skin test (TST). 7 To perform this test, tuberculin (also known as purified protein derivative, or PPD) is injected intradermally (between skin layers). The immune system of most persons with tuberculosis (TB) infection will recognize the tuberculin, causing a reaction in the skin. Repeated TSTs do not produce hypersensitivity.
Interpretation of a TST reaction considers the size of the measured induration (a firm, palpable swelling) and the patient's individual risk of acquiring TB infection or the risk of progressing to TB disease if infected. 8 Based on this risk stratification, there are three different cut-offs for defining a positive TST reaction:  Greater than or equal to 5 mm of induration  Greater than or equal to 10 mm of induration  Greater than or equal to 15 mm of induration 9 For detailed information about the interpretation of the TST, see the "Interpretation of the Tuberculin Skin Test" section of this chapter, below.
The Mantoux TST can be safely administered to all persons, including pregnant women, 10 persons who have previously been vaccinated with Bacille Calmette-Guérin (BCG), 11 and human immunodeficiency virus (HIV)-infected persons. However, the following should be noted:  An IGRA (discussed below), if available, is preferred for people who have received a previous BCG vaccine.
 Persons with a documented prior positive TST do not need another TST, as it is likely to remain positive, even after treatment for LTBI.
 Persons with a previous allergic reaction to TST should not be retested; an IGRA should be used if testing is indicated.
 The Mantoux TST should not be administered until four weeks after vaccination with live-virus vaccines.
 Anergy testing in conjunction with TST is not helpful or recommended.
If the person being tested is a contact, follow the procedures outlined in Chapter 10, "Contact Investigation." Bacille Calmette-Guérin Vaccine BCG vaccines are live vaccines derived from a strain of Mycobacterium bovis. In many parts of the world where TB is highly prevalent, the vaccine is used to reduce the risk of severe disseminated TB and TB meningitis in young children. 12 For various reasons, including the low risk of severe TB disease in young children in the United States and variable efficacy of the vaccine in adults, BCG vaccine is generally not recommended in the United States, but may be used rarely for certain contacts of cases or healthcare workers traveling abroad to work in high-risk settings. 13 A history of BCG vaccination is not a contraindication to tuberculin skin testing; however, a history of BCG vaccination can cause a false positive TST reaction (either initially or as a boosted reaction). For this reason, IGRA is the preferred testing strategy for individuals who have a history of BCG vaccination. 14 However, if IGRA testing is not available, TST testing can be administered to BCG-vaccinated individuals and interpreted in the same manner as in those who have no history of BCG vaccination. 15 For example, for an individual born in a country in which TB is common, the cut-off for a positive TST is 10 millimeters or more regardless of BCG vaccination history (unless other risk factors, such as HIV infection, are present that indicate a lower cut-off for a positive TST reaction).
Foreign born individuals being evaluated for LTBI may not know their personal BCG vaccination history. For assistance with determining if a patient may have received BCG in their country of origin, refer to: http://www.bcgatlas.org/
Documented Prior Positive Tuberculin Skin Test
Persons who have tested positive in the past and can provide documentation of their status should not have another TST. Instead, they should be screened with a chest radiograph or have a TB symptom assessment questionnaire administered to identify any symptoms of TB disease. 16 
Live-Virus Vaccines
Vaccines with live viruses (including measles, mumps, rubella, oral polio, varicella, yellow fever, and oral typhoid) may interfere with TST reactivity and cause a false negative reaction. To minimize false-negative TST reaction, TST should be done either on the same day that the live vaccine is administered or at least one month after vaccination. The decision on which approach to take should consider both the urgency of the TST as well as the likelihood that the individual will return in one month for an additional two visits (for administration and reading of the TST, respectively). 17 
Booster Phenomenon and Two-Step Testing
Some people infected with M. tuberculosis may have a negative reaction to a single TST if many years have passed since they became infected. However, they may have a positive reaction to a subsequent TST because the initial test has stimulated their ability to react to the test. This is commonly referred to as the "booster phenomenon" and may incorrectly be interpreted as a skin test conversion (going from negative to positive).
For this reason, the "two-step method" is recommended at the time of initial testing for individuals who may be retested periodically (e.g., health care workers). The two-step method involves an initial TST for the individual. Next steps are as follows:
• If the first TST result is positive, consider the person infected and evaluate and treat the person accordingly.
• If the first test result is negative, the TST should be repeated in 1-3 weeks.
o If the second test result is positive, consider the person infected and evaluate and treat the person accordingly o if both steps are negative, consider the person uninfected and classify the TST as negative at baseline testing (see Figure 1 ). 18
When IGRAs are used for serial testing, there is no need for a second test because boosting does not occur. 
Administration of the Tuberculin Skin Test
The TST should be placed by a healthcare worker who has received appropriate training and is following written protocols.
How to Administer a Tuberculin Skin Test 
5.
Wash hands using appropriate hand-washing technique. Follow your institution's standard precautions for infection control.
6.
The injection should be placed on the palm-side-up surface of the forearm, about two to four inches below the elbow. Your local institutional policy may specify the right or left forearm for the skin test. The area selected should be free of any barriers to placing and reading the skin test, such as muscle margins, heavy hair, veins, sores, tattoos, or scars.
7.
After choosing the injection site, clean the area with an alcohol swab by circling from the center of the site outward. Allow the site to dry completely before the injection.
8.
Using a disposable tuberculin safety needle and syringe, inject 0.1 ml of PPD tuberculin containing 5 tuberculin units (TU) intradermally with the needle bevel facing upward. Because some of the tuberculin solution can adhere to the inside of the plastic syringe, the skin test should be given as soon as possible after the syringe is filled.
9.
The injection should produce a discrete, pale elevation of the skin (a wheal) 6 to 10 mm in diameter. Note: If a 6 to 10 mm wheal is not produced, repeat the test on the opposite arm or the same arm, 2 inches from the original site.
10.
Record the date and time of TST administration, location of injection site, dose, name of person who administered the test, name and manufacturer of tuberculin product used, lot number, expiration date, and the reason for testing. 19 
Measurement of the Tuberculin Skin Test
A trained healthcare worker should read the TST 48 to 72 hours after the intradermal injection. Patients should never be allowed to read their own TSTs. 20  A positive reaction is considered valid even if it is read more than 72 hours after intradermal injection.
 If the results appear negative and more than 72 hours have passed, the test should be repeated. It can be repeated immediately, or after one week, if two-step testing is required.
A topic entitled "Two-Step Tuberculin Skin Testing" topic can be found in Chapter 16, "Infection Control" of this manual.
How to Measure a Tuberculin Skin Test
1. Measure the TST site crosswise to the axis of the forearm (from the thumb side of the arm to the little finger side of the arm or vice versa).
2.
Induration is a hard, dense, raised formation. Measure only induration hardness and not swelling around the site of the injection. Do not measure erythema (redness). A TST with erythema, but no induration, is nonreactive.
3.
Record the test result in mm, not as "positive" or "negative." An exact reading in mm may be necessary to interpret whether conversions occur on a subsequent test. Record a TST with no induration as "0 mm." Where there is induration, do not round off the reading, but record it exactly as read.
4.
Report adverse reactions to a TST (e.g., blistering, ulcerations, necrosis) to the FDA's MedWatch Program at 1-800-FDA-1088, or via the Internet at this hyperlink: http://www.fda.gov/medwatch/ .
Interpretation of the Tuberculin Skin Test
TSTs should be interpreted by a trained healthcare worker.
Call the Idaho State TB program at (208) 334-5939 for consultation regarding TST reactions for which interpretation and medical follow-up are unclear.
How to Interpret a Tuberculin Skin Test
Use the table below. 
Interferon-Gamma Release Assay (IGRA) Testing
IGRAs are used to determine if a person is infected with M. tuberculosis by measuring the immune response to TB proteins in whole blood. Blood specimens are mixed with peptides that simulate antigens derived from M. tuberculosis and controls. In a person infected with M. tuberculosis, the white blood cells in the person's blood specimen recognize the simulated antigens and release interferon-gamma (IFNγ); results are based on the amount of IFNγ released. 23 The U.S. Food and Drug Administration (FDA) approved IGRAs commercially available in the United States include:
• QuantiFERON ® -TB Gold-in-Tube test (QFT-GIT) or QuantiFERON-TB Gold Plus (QFT-Plus)
Populations in which IGRAs are preferred for testing: o Persons who have received BCG (either as a vaccine or for cancer therapy); and o Persons from groups that historically have poor rates of return for TST reading.
According to the American Academy of Pediatrics, TST is preferred over IGRAs for testing children less than 2 years of age. 24
Interpretation of IGRA Results
The interpretation of IGRAs is based on the amount of IFN-γ released (QFT-GIT), or on the number of cells that release IFN-γ (in T-SPOT®). TB laboratories should provide both the qualitative and quantitative results.
• Qualitative results are reported as positive, negative, indeterminate or borderline.
• Quantitative results are reported as numerical values that include a response to the TB antigen and 2 controls, nil and mitogen. Quantitative results may be useful for clinical decision making in individual cases, in combination with risk factors.
The antigens, testing methods, and interpretation criteria for IGRA results are outlined in Table 1 . When the initial test is negative and:
• The risk for infection, progression to disease, and/or a poor outcome is high (e.g., HIV-infected persons or children under 5 years of age who are exposed to a person with infectious TB) and suspicion for M. tuberculosis infection is high.
• There is clinical suspicion for TB disease (e.g., signs, symptoms, and/or radiographic evidence suggestive of TB disease) and confirmation of M. tuberculosis infection is desired prior to initiating treatment.
When the initial test is positive and:
• Additional evidence of infection is required to encourage acceptance and adherence to treatment (e.g., foreign-born persons who believe their positive TST is due to BCG). • The person has a low risk of both infection and progression from infection to TB disease. Requiring a positive result from the second test as evidence of infection increases the likelihood that the test reflects infection. An alternative is to assume, without additional testing, that the initial result is a false positive or that the risk for disease does not warrant additional evaluation or treatment, regardless of test results.
In addition, repeating an IGRA or performing a TST might be useful when the initial IGRA result is indeterminate, borderline, or invalid and a reason for testing persists.
Remember, even multiple negative results from any combination of these tests cannot entirely exclude M. tuberculosis infection.
Human Immunodeficiency Virus Screening
The risk of progression from LTBI to active TB disease is 7% to 10% each year for those with both LTBI and untreated HIV infection. Those with LTBI who are not HIV-infected have a 10% risk over their lifetime. Thus, the risk of progression to TB disease is much higher for those who are HIV infected. This risk is reduced with antiretroviral therapy for HIV, but is still higher than that in HIV-negative persons with LTBI. 25 HIV-infected persons should be tested for LTBI as soon as their HIV status becomes known. A negative TST or IGRA result does not exclude LTBI as they may have a compromised ability to react to tests for TB infection. Annual testing should be considered for HIV-infected persons who are TST or IGRA negative on initial evaluation, and who have a risk for exposure to M. tuberculosis. The usefulness of anergy testing in HIV-infected individuals or others has not been demonstrated; therefore, it is not recommended.
After the initiation of antiretroviral therapy (ART), repeat testing for LTBI is recommended for HIV-infected persons previously known to have negative TST or IGRA results. This is because the immune response may be restored by adequate treatment. 
Chest Radiography
Chest x-rays help differentiate between LTBI and pulmonary TB disease in individuals with positive tests for TB infection. All individuals with a positive TST or IGRA being considered for LTBI treatment should undergo a chest radiograph to rule out pulmonary TB disease even in the absence of symptoms. 27 A posterior-anterior radiograph of the chest is the minimum standard view used for the detection and description of chest abnormalities in adults. In most instances, a lateral view is obtained; other views (e.g., lordotic) or additional studies (e.g., computed tomography [CT] scans) may be necessary.
Children younger than five years of age should always receive posterioranterior and lateral radiographs. 28
For more information on chest radiography, refer to the Francis J. Curry National Tuberculosis Center's Radiographic Manifestations of Tuberculosis: A Primer for Clinicians (Francis J. Curry National Tuberculosis Center Web site; 2006) at: http://www.nationaltbcenter.ucsf.edu/products/product_details.cfm?productID= EDP-04 .
For persons recently exposed to TB, follow the procedures for testing and evaluation in Chapter 10, "Contact Investigation."
Sputum Examination for AFB Smear and Culture
Sputum examination is usually indicated for persons with positive test results for TB infection and either an abnormal chest radiograph or the presence of respiratory symptoms of greater than three weeks' duration (even when the chest radiograph is normal). 29
Physical Examination and Medical History
Physical examination and medical history should be done as part of the evaluation for latent TB infection. The history should include: 30 • previous positive tests for TB infection • previous treatment for LTBI or TB disease • previous severe pulmonary disease • risk assessment for liver disease • drug allergies Written documentation of a previously positive TST or IGRA result is required in order to forego testing someone with an indication for TB testing; a patient's verbal history is not sufficient. 31 If no written documentation is available, the test should be repeated, unless a history of severe allergic reaction to a previous TST is given, in which case an IGRA should be done.
